We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a Senate hearing yesterday, National Institutes of Health Director Francis Collins applauded AstraZeneca’s decision to halt its phase 3 COVID-19 vaccine trial due to an unexplained illness — and said the incident should reassure the public that companies are not compromising when it comes to the safety of their vaccine candidates. Read More
Three House Democrat committee chairs are demanding that HHS Secretary Alex Azar detail how the department is gearing up for COVID-19 vaccine distribution, how it is working to increase public faith in a vaccine and how it will ensure its decisions aren’t influenced by politics. Read More
President Trump’s efforts to coax a new strategy from industry to lower drug prices by means of a brandished executive order have been met with silence so far, and the administration is running out of time to show some headway on drug pricing before the Nov. 3 presidential election. Read More
In addition to the risk of allergic contact dermatitis, the agency also found that there is inadequate evidence that the ingredient in the drug is effective. Read More
After returning from a month-long congressional hiatus, Senate Majority Leader Mitch McConnell (R-Ky) unveiled a proposed coronavirus relief package on Tuesday that includes $31 billion for COVID-19 medical countermeasures. Read More
The panel said there is no concern about the risk of liver injury for single-dose ulipristal acetate, which is used for emergency contraception. Read More
Multiple drugmakers have reportedly drafted a public pledge not to seek FDA approval of their COVID-19 vaccines until they meet certain safety and efficacy standards even as President Trump said a vaccine may be ready as soon as October. Read More
The FDA has updated its guidance on the use of convalescent plasma to treat COVID-19 or in clinical trials of treatments to take account of the administration’s Aug. 23 Emergency Use Authorization (EUA). Read More
Democrats on the House Energy and Commerce committee urged HHS Secretary Alex Azar yesterday to protect the 340B Drug Pricing Program following threats from several drugmakers to end discounts to hospitals that they pass on to patients under the program. Read More
The FDA has ousted another high-ranking communications officer following fallout from FDA Commissioner Stephen Hahn’s misrepresentation of convalescent plasma as a COVID-19 treatment. Read More
Drugmakers are concerned that President Trump may expedite implementation of an executive order aimed at lowering drug prices by ordering HHS to issue an interim final rule ahead of the Nov. 3 presidential election. Read More
California this week passed a bill that would allow the state to partner with generic drugmakers to manufacture its own generics, making it the first state to try this approach to lowering drug prices. Read More